Small molecule TK inhibitors (TKIs, e.g. imatinib, dasatinib, ruxolitinib, midostaurin) have clinical activity in certain TK-driven acute leukemias but are more effective in combination with other targeted or chemotherapeutic agents4–11. This evidence concerns the gene TKT and acute leukemia.